Neuropathic pain has proven to be a difficult condition to treat, so investigational therapy has been sought that may prove useful, such as the use of sigma‐1 antagonists. Haloperidol (HAL) is a compound that shows a high affinity with these receptors, acting as an antagonist. Therefore, the objective of this study was to demonstrate its effect in an experimental model of neuropathic pain and corroborate its antagonistic action of the sigma‐1 receptors under these conditions. BD‐1063 was used as a sigma‐1 antagonist control, and gabapentin (Gbp) was used as a positive control. The antihyperalgesic and anti‐allodynic effects of the drugs were determined after single‐dose trials. In every case, the effects increased in a dose‐dependent manner. HAL had the same efficacy as both BD‐1063 and Gbp. In the analysis of pharmacological potency, in which the ED₅₀ were compared, HAL was the most potent drug of all. The effect of HAL on chronic constriction injury (CCI) rats was reversed by the sigma‐1 agonist (PRE‐084). HAL reversed the hyperalgesic and allodynic effects of PRE‐084 in naïve rats. The dopamine antagonist, (‐)‐sulpiride, showed no effect in CCl rats. These results suggest that HAL presents an antinociceptive effect via sigma‐1 receptor antagonism at the spinal level in the CCl model.